Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- Acronyms LEN01T
- Sponsors Eisai Co Ltd
- 23 Dec 2016 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.
- 20 May 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 31 Mar 2015 New trial record